James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment
2014 ASH Annual Meeting
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.
James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, discuss the diagnosis and genetics of ALL, differences in treating younger and older patients, and the latest data on the use of tyrosine kinase inhibitors, monoclonal antibodies, and CAR T cells.
Sagar Lonial, MD
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Results for the 1703 Phase Ib/II Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma,” presented by Paul G. Richardson, MD; abstract 84, “Safety and Efficacy of Daratumumab With Lenalidomide and Dexamethasone in Relapsed or Relapsed/ Refractory Multiple Myeloma,” presented by Torben Plesner, MD; and “A Phase Ib Dose Escalation Trial of SAR650984 (Anti–CD-38 mAb) in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma,” presented by Thomas G. Martin III, MD.
